Sat, Aug 30, 2014, 2:50 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

OCZ Technology Group Inc Message Board

vvvvvvrebel89130 1621 posts  |  Last Activity: 22 hours ago Member since: Sep 15, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • blocks that went thru earlier in the day were those orders that they made prior to the close

    btw, 217k shrs + 17 pennies already;

    Sentiment: Strong Buy

  • Reply to

    1MM shrs in 30 mins

    by vvvvvvrebel89130 22 hours ago
    vvvvvvrebel89130 vvvvvvrebel89130 22 hours ago Flag

    i'm actually impressed you can spell RA

    Sentiment: Strong Buy

  • vvvvvvrebel89130 by vvvvvvrebel89130 22 hours ago Flag

    stampede

    Sentiment: Strong Buy

  • vvvvvvrebel89130 by vvvvvvrebel89130 Aug 29, 2014 1:59 PM Flag

    4 Biotechs That Might Be Bought Soon
    By AMY REEVES, INVESTOR'S BUSINESS DAILY
    Posted 11:53 AM ET
    Email Print Reprints Comment

    inShare

    The recent announcement that Roche (OTCPK:RHHBY) will buy InterMune (NASDAQ:ITMN) for $8.3 billion brought new life to M&A speculation in the biotech industry, which had been relatively neglected as the buzz focused on tax-inversion deals by biopharmaceutical companies.

    While IBD has no greater ability than anyone else to predict the future, here are four biotech stocks that have been named as possible targets on the Street, with stock-moving results.

    • Achillion Pharmaceuticals (NASDAQ:ACHN): This stock first became the subject of buyout speculation in June, when big pharma Merck (NYSE:MRK) paid a hefty premium to acquire Idenix Pharmaceuticals for its hepatitis C drug. Achillion is developing a drug in the same class as Idenix's, and many observers see it as the only real buyout target left in this field.

    View Enlarged Image

    The stock consolidated through July and early August, as investors and analysts debated the soundness of the company's technology and business model. It got a new bump on Aug. 18, when Deutsche Bank analyst Alethia Young upgraded it to buy, saying that her concerns about execution had been allayed. The stock rose more than 20% in the two days following the InterMune announcement, touching a new high of 12.06. In late-morning trading on the stock market today it was near 11.40, down a fraction.

    • Intercept Pharmaceuticals (NASDAQ:ICPT): Valuation on this stock has gotten very high — more than $6 billion market cap for a company that doesn't even have a product out yet. But it's still being mooted about as a buyout prospect as it continues to roll out good data on its lead product, obetacholic acid, as a treatment for fatty liver disease. Many analysts see liver disease as a logical extension for the current hepatitis C players, especially Gilead Sciences (NASDAQ:GILD), which some analysts see as "due"

    Sentiment: Strong Buy

  • that price

    Sentiment: Strong Buy

  • vvvvvvrebel89130 by vvvvvvrebel89130 Aug 29, 2014 12:05 PM Flag

    gl longs

    Sentiment: Strong Buy

  • Reply to

    aggie + 10 1/2

    by vvvvvvrebel89130 Aug 28, 2014 7:03 PM
    vvvvvvrebel89130 vvvvvvrebel89130 Aug 29, 2014 8:20 AM Flag

    lol; i had heard about the furniture bet and forgot it; you guys have 3 qb's; hill, kid there now kid next year from allen; one or more will transfer as hill has that job locked up; i luved the look on the backup's face when they showed him on the sidelines "daum, i'm transferring"; if i'm strong i'm going hard after the allen kid; i don't care if he's got aggie roots; hes not going there to hold a clipboard

    he won 2 states; scary is he should have won 3 as desoto stopped him on the 1 inch line on the last play of a playoff game his sr year that i think his coach blew; huge game tonite for slc as they play austin westlake with todd dodge coming home; would luv to see that game; looks like lee and central are in good shape; lee plays slc next week i think in midland;

    mutiple slc qb's at major level; mcelroy won championship with tide, another went to couger high

    calvin hills son i believe

    looks like you finally found a d

    congrat

    Sentiment: Strong Buy

  • vvvvvvrebel89130 by vvvvvvrebel89130 Aug 28, 2014 7:03 PM Flag

    you guys look great; kicking myself for not playing the over

    charley strong needs to go hard for the allen kid; no way he comes to a&m now; looks like kenny hill has it locked up; his backup didn't look too happy, lol; he sees the handwriting on the wall; betcha he transfers very soon

    maybe to us as we need a qb real bad; we'll take him or the allen kid

    hang on

    Sentiment: Strong Buy

  • Reply to

    stock pinned to $11.50 line since Tues

    by vvvvvvrebel89130 Aug 28, 2014 3:14 PM
    vvvvvvrebel89130 vvvvvvrebel89130 Aug 28, 2014 6:56 PM Flag

    i suspect talks if they started started around the early aug time frame when the prelim results were announced so to speak by the ceo

    i don't think talks will take that long; assuming no deal before the results, if the results are as good as we suspect, there will be a firestorm and perhaps an open bidding process

    also my point on the best interest of achn and us frankly is this

    cut a deal now for lets say $40 or wait until the results are released and the stock spikes to $20-$40 and then cut a;deal for $60 or more?

    before anyone thinks those numbers are insane, i was in srpt in 2013 when on a monday it closed at $14; muscular dystrophy results were released and the stock spiked to $31 where it held during p/m; within 30 mins of market open, srpt was trading at $45; pull up a 5 yr chart to see; $31 point gain in one day; could happen here

    fwiw, i was in bidu's ipo when it ipo'd at $50 and peaked THAT DAY at $152; yep 100 pt day

    good talking to you today; i learned a lot and good discussion

    someone is buying this up

    Sentiment: Strong Buy

  • doesn't get much more obvious than this

    something is buying up all the shrs RA dumped and they're buying at all time highs which should tell you something

    keep an eye on 11.50 tomorrow
    gl longs

    Sentiment: Strong Buy

  • Reply to

    stock pinned to $11.50 line since Tues

    by vvvvvvrebel89130 Aug 28, 2014 3:14 PM
    vvvvvvrebel89130 vvvvvvrebel89130 Aug 28, 2014 3:41 PM Flag

    someone building a position at virtually the all time highs with pending results ties to your comment about leak of the results

    float is being soaked up and when "they" who they are is done, then this will move

    also, interesting building a position in front of a long weekend

    i don't think a buyout is emminent as it's in achn's best interests to release the results and then negotiate

    Sentiment: Strong Buy

  • vvvvvvrebel89130 by vvvvvvrebel89130 Aug 28, 2014 3:14 PM Flag

    pull up a chart; hugging $11.50 +/- 20 pennies

    suspect someone is buying in here; soaking up the inside sells

    no way a stock with this volatility randomly trades flat for couple of days

    gl longs

    Sentiment: Strong Buy

  • Reply to

    BOD meetings in 3-4 locations as follows:

    by binary_departure101 Aug 28, 2014 11:50 AM
    vvvvvvrebel89130 vvvvvvrebel89130 Aug 28, 2014 11:56 AM Flag

    funniest post i've seen in a long time was here not too long ago when a poster said gild buying achn would be a rounding error for gild when it came to money

    as you've pointed out, gild's currency, their stock is increasing by the minute

    also, checked their last financials; gild bought over 1bb in gild stock last q

    have to think they have a better use for the cash than buying their own stock at all time highs

    gl

    Sentiment: Strong Buy

  • vvvvvvrebel89130 by vvvvvvrebel89130 Aug 28, 2014 11:52 AM Flag

    When Will M&A Come To The Hepatitis C Space?
    Aug. 28, 2014 10:48 AM ET | 9 comments | Includes: ACHN, CNAT, GILD

    Disclosure: The author is long ACHN, CNAT, GILD. (More...)
    Summary

    Biotech InterMune was taken out by Roche for over $8 billion yesterday in a deal that had an almost 40% buyout premium.
    Given the strength of M&A this year and the huge interest in Hepatitis C space thanks to Gilead's Sovaldi, it is logical to assume this space could see M&A activity.
    Two possible takeout in the Hepatitis C space are profiled below.

    My regular readers on Seeking Alpha and Real Money Pro know that the biggest position in my portfolio is Gilead Sciences (NASDAQ:GILD) which has been a rocket since the stock's dip into the mid-$60s in March in a quick and brutal shakeout in the biotech sector. Since then, the stock has been on fire and should continue to rise based primarily on the blowout results from its blockbuster Hepatitis C (HCV) drug Sovaldi.

    (click to enlarge)

    Yesterday, Roche acquired InterMune (NASDAQ:ITMN) in an over $8 billion deal with an almost 40% buyout premium. The main attraction for Roche of acquiring InterMune is the company's drug for idiopathic pulmonary fibrosis, a disease that causes tissue deep in the lungs to become thick and scarred over time. M&A activity has been strong throughout 2014 in U.S. equities and is approaching 2007 peak levels and I doubt this is last buyout in the sector this year.

    This got me to thinking on when a large player is going to take a shot at the Hepatitis C arena given Sovaldi's blowout sales, high price tag ($84,000 per 12 week regiment domestically) and huge international market. Gilead is definitely the largest position I have addressing this market. However, recently I also took positions in two other small, speculative plays that are developing products to address this huge market.

    I have out of the money covered calls sold against a good portion of these positions given the huge premiums availab

    Sentiment: Strong Buy

  • Reply to

    More on the 3422 trial underway

    by magnam_pi Aug 28, 2014 10:49 AM
    vvvvvvrebel89130 vvvvvvrebel89130 Aug 28, 2014 11:27 AM Flag

    so, dr gane completes the 50mg test; he shares the results with achn and they say cool, escalate the dose

    this is from the 3122 pr which is 8 days out from the earlier update

    as you said, no news is good news and it also explains the ceo's confidence below in stating "we anticipate" instead of the standard, "if results are positive" or "pending the results" wishy washy weasely ceo talk

    i also looked at dr gane's background; he's the man; impeccable credentials and the fact he ran the trials for gild and idix certainly bodes well and i'm sure is a reason why achn chose him

    great info

    thanks

    We expect that Phase 1 proof-of-concept results with ACH-3422 will be reported during the fall of this year, which we anticipate will lead to the start of a Phase 2 combination program to evaluate our proprietary doublet regimen for an eight week, or potentially shorter, treatment regimen for HCV that will begin before the end of 2014."

    Sentiment: Strong Buy

  • Reply to

    More on the 3422 trial underway

    by magnam_pi Aug 28, 2014 10:49 AM
    vvvvvvrebel89130 vvvvvvrebel89130 Aug 28, 2014 11:13 AM Flag

    mag

    how do you know achn is updated as the trial goes forward?

    this trial isn't double blinded?

    i thought for sure it was

    hope i'm wrong, lol

    thanks

    After the dosing and lab tests on each healthy or HCV infected cohort is completed, the results are turned over to the company for analysis and recommendations. So the company already knows the effectiveness of 3422 as a function of the dose and can project the results to higher doses. It is po

    Sentiment: Strong Buy

  • The IPO for Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is open for trading. The stock is trading at $11.84 after pricing 4,500,000 shares at $11.50 per share, below the expected $14-$16 range.

    Sentiment: Strong Buy

  • Reply to

    Biotechworld15

    by macugen_rules Aug 27, 2014 9:13 PM
    vvvvvvrebel89130 vvvvvvrebel89130 Aug 27, 2014 9:24 PM Flag

    and i bet they rec 60k in options in the next couple of days just like the last sell

    they will be made whole

    sell 3mm shrs, rec options for 3mm shrs

    nice when you can do that

    Sentiment: Strong Buy

  • Reply to

    Everyone Calm Down about RA selling

    by biotechworld15 Aug 27, 2014 6:30 PM
    vvvvvvrebel89130 vvvvvvrebel89130 Aug 27, 2014 8:12 PM Flag

    thats my question; short int didn't decrease on the 15th report i'm relatively sure the shorts didn't buy the shrs to cover; so who did?

    are all those shrs and these just sloshing around and being traded/bought by retail or did some other tute buy them?

    we wont know unless a tute becomes a 5% owner in which case they would have to file a 13G in 5 days or when the Fidelitys, Vanguards, etc of the world file their quartery updates which won't be due until nov 15, 45 days after this quarter's close

    Sentiment: Strong Buy

OCZ
0.050.00(0.00%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.